BCD-178
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BCD-178, covering 2025-07-20 to 2025-07-20. Get the full timeline:
Most recent: Clinical Trial Update: Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer [Phase 3]